Keywords: |
cancer survival; event free survival; clinical trial; advanced cancer; cancer combination chemotherapy; monotherapy; nonhuman; treatment planning; antineoplastic agents; clinical trials as topic; cancer adjuvant therapy; cancer radiotherapy; chemotherapy, adjuvant; neoadjuvant therapy; research design; outcome assessment; antineoplastic agent; breast cancer; mastectomy; epidermal growth factor receptor 2; breast neoplasms; cancer mortality; cancer hormone therapy; antibodies, monoclonal; drug response; cancer relapse; short survey; trastuzumab; breast metastasis; study design
|